EyePoint Pharmaceuticals (NasdaqGM:EYPT) Q3 2025 Earnings Call November 05, 2025 08:30 AM ET Speaker2Good morning. My name is Antoine, and I will be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals Third Quarter 2025 Financial Results and Recent Corporate Developments conference call. There will be a question-and-answer session to follow at the completion of the prepared remarks. Please be advised that this call is being recorded at the company's ...

EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -10.39%. A quarter ago, it was expected that this drug delivery technology company would post a loss of $0.67 per share when it actually produced a loss of $0.85, delivering a surprise of -26.87%.Over the last f ...

– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 – – Announced initiation of pivotal Phase 3 DME program consisting of two identical non-inferiority trials, COMO and CAPRI; first patient dosing anticipated in Q1 2026 – – Announced preclinical data demonstrating DURAVYU’s potential as a multi-target treatment inhibiting both VEGF-mediated vascular permeability and IL-6 mediated inflammation, key contributors to wet AMD and D ...

WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 5, 2025 to report its third quarter 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the au ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shared details on Tuesday about its pivotal Phase 3 program of Duravyu (vorolanib intravitreal insert) for diabetic macular edema (DME) and began first patient dosing, anticipated in the first quarter of 2026.DME is the leading cause of vision loss in type 1 and type 2 diabetes patients. Damaged blood vessels leak fluid into the macula, the central portion of the retina responsible for sharp vision needed for routine tasks such as driving or reading.Phase 3 Clini ...

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $12.00 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 1,500,000 share ...

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock. All of the shares are being offered by EyePoint. In addition, EyePoint intends to grant the underwriters an option for a period of 30 days to purchase up ...

C EYEPOINT Investor Presentation October 2025 © 2025 EyePoint. All Rights Reserved. E Legal Disclaimers /Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Liligation Reform Act of 1995, and are inherently subje potentially inacourale assumpions. All statements that actives, events or developments that we intend, expect, plan or believe may ocuri in he future, aer ofonerelophig sta investigational sustained release treatments for wet AMD; our ...

– DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 – – New preclinical data demonstrates that vorolanib, the active drug in DURAVYU, inhibits both VEGF-mediated vascular permeability and IL-6 mediated inflammation, key contributors to wet AMD and DME –  – IL-6 finding supports the compelling efficacy data observed in the Phase 2 VERONA DME trial and underscores DURAVYU as a ...

EyePoint Pharmaceuticals (EYPT) 2025 Conference September 03, 2025 02:45 PM ET Speaker0Thanks for joining our fireside chat with EyePoint Pharmaceuticals. I'm Jennifer Kim, one of the biotech analysts here at Cantor, and I'm excited to have with us George Elston, CFO. George, it's always good to have you. Thanks for being here.Speaker1Thank you, Jennifer, and thanks to Cantor for having EyePoint here today. Excited to talk to you.Speaker0Always. So a lot of exciting things happening at EyePoint right now. M ...